2025 Q3 -tulosraportti
Vain PDF
71 päivää sitten
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,35VWAP
Alin
11,34VaihtoMäärä
64,4 5 441 045
VWAP
Ylin
12,35Alin
11,34VaihtoMäärä
64,4 5 441 045
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 11.6.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sittenJohn Leonard said this at JPM on January 14 Yes, I mean, the patient – I mean, I can describe the clinical course, which I think is helpful for understanding. This is a patient who participated in the study, an 82-year-old man, who received the drug and just over three weeks later reported abdominal pain to his treating physician. His doctor said: “Go to the emergency room and they will look at you.” When he was there, it was observed that he had elevated transaminases. He was admitted to the hospital for observation. During the time he was hospitalized – and the hospital, as far as we can tell, took excellent care of him – the medical staff gave him, among other things, steroids. Approximately one week into his hospital stay, his condition deteriorated, he was evaluated, and free air was found in his abdomen. He underwent surgery and a perforation of approximately five centimeters (two inches) was found in the duodenum, connected to a duodenal ulcer that was also discovered. The patient never really recovered from this. He subsequently had a very stormy course, with episodes of hypoperfusion, septicemia, and ultimately the family chose to withdraw life support. He did not die of liver failure, which I believe has been misunderstood by some observers here. It is highly unlikely, in our assessment, that what the patient experienced in the form of liver damage, as manifested by elevated transaminases, was attributable to the other underlying process. The death was ultimately attributed to sepsis resulting from the perforated ulcer.
·17 t sittenAfter yesterday's presentation, Intellia appears more robust than the share price reflects. Lonvo-z (HAE) is over-recruited in Phase III with very strong Phase I/II data, high physician and patient interest, and a realistic plan towards topline data mid-2026 and possible launch in 2027. The TTR program (nex-z) shows deep, sustained effect, and the clinical hold is due to a single patient and not a fundamental safety problem. Management is actively in dialogue with the FDA, and historically, clinical holds are typically resolved over months, not years — which could trigger a new re-rating when it happens. In the short term, many investors expect a stable consolidation around 12–14 USD. If the hold is clarified and HAELO data are strong, some analysts see an upside of +30–50 % (e.g., 15–18 USD), and in more bullish scenarios, we could see price targets above 20–30 USD, especially if commercial value starts to be priced in. It is a stock with asymmetric risk/reward: the downside is relatively subdued after bottoming out and stabilization, while the next regulatory news and data can provide clear share price movements. Overall assessment: undervalued with clear milestones to follow.
·10 t sittenWith two phase-3 trials in the pipeline, it's probably a bit of a stretch to say that the downside is mitigated. There is a risk that these trials might have to be dropped entirely, the patient died after all.- ·8.1.Intellia insider Fred E Cohen has bought 150,000 shares yesterday https://ir.intelliatx.com/node/12396/html·8.1.Exciting! Do you think there will be news soon?
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.
·12.12.2025Have positions in both Intellia, Beam and CRISPR - believe in this sector and that this is the future and play my cards broadly, most exposed to CRISPR, and smaller positions in Intellia and Beam respectively.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
71 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenJohn Leonard said this at JPM on January 14 Yes, I mean, the patient – I mean, I can describe the clinical course, which I think is helpful for understanding. This is a patient who participated in the study, an 82-year-old man, who received the drug and just over three weeks later reported abdominal pain to his treating physician. His doctor said: “Go to the emergency room and they will look at you.” When he was there, it was observed that he had elevated transaminases. He was admitted to the hospital for observation. During the time he was hospitalized – and the hospital, as far as we can tell, took excellent care of him – the medical staff gave him, among other things, steroids. Approximately one week into his hospital stay, his condition deteriorated, he was evaluated, and free air was found in his abdomen. He underwent surgery and a perforation of approximately five centimeters (two inches) was found in the duodenum, connected to a duodenal ulcer that was also discovered. The patient never really recovered from this. He subsequently had a very stormy course, with episodes of hypoperfusion, septicemia, and ultimately the family chose to withdraw life support. He did not die of liver failure, which I believe has been misunderstood by some observers here. It is highly unlikely, in our assessment, that what the patient experienced in the form of liver damage, as manifested by elevated transaminases, was attributable to the other underlying process. The death was ultimately attributed to sepsis resulting from the perforated ulcer.
- ·17 t sittenAfter yesterday's presentation, Intellia appears more robust than the share price reflects. Lonvo-z (HAE) is over-recruited in Phase III with very strong Phase I/II data, high physician and patient interest, and a realistic plan towards topline data mid-2026 and possible launch in 2027. The TTR program (nex-z) shows deep, sustained effect, and the clinical hold is due to a single patient and not a fundamental safety problem. Management is actively in dialogue with the FDA, and historically, clinical holds are typically resolved over months, not years — which could trigger a new re-rating when it happens. In the short term, many investors expect a stable consolidation around 12–14 USD. If the hold is clarified and HAELO data are strong, some analysts see an upside of +30–50 % (e.g., 15–18 USD), and in more bullish scenarios, we could see price targets above 20–30 USD, especially if commercial value starts to be priced in. It is a stock with asymmetric risk/reward: the downside is relatively subdued after bottoming out and stabilization, while the next regulatory news and data can provide clear share price movements. Overall assessment: undervalued with clear milestones to follow.·10 t sittenWith two phase-3 trials in the pipeline, it's probably a bit of a stretch to say that the downside is mitigated. There is a risk that these trials might have to be dropped entirely, the patient died after all.
- ·8.1.Intellia insider Fred E Cohen has bought 150,000 shares yesterday https://ir.intelliatx.com/node/12396/html·8.1.Exciting! Do you think there will be news soon?
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.
- ·12.12.2025Have positions in both Intellia, Beam and CRISPR - believe in this sector and that this is the future and play my cards broadly, most exposed to CRISPR, and smaller positions in Intellia and Beam respectively.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,35VWAP
Alin
11,34VaihtoMäärä
64,4 5 441 045
VWAP
Ylin
12,35Alin
11,34VaihtoMäärä
64,4 5 441 045
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 11.6.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 |
2025 Q3 -tulosraportti
Vain PDF
71 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 11.6.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenJohn Leonard said this at JPM on January 14 Yes, I mean, the patient – I mean, I can describe the clinical course, which I think is helpful for understanding. This is a patient who participated in the study, an 82-year-old man, who received the drug and just over three weeks later reported abdominal pain to his treating physician. His doctor said: “Go to the emergency room and they will look at you.” When he was there, it was observed that he had elevated transaminases. He was admitted to the hospital for observation. During the time he was hospitalized – and the hospital, as far as we can tell, took excellent care of him – the medical staff gave him, among other things, steroids. Approximately one week into his hospital stay, his condition deteriorated, he was evaluated, and free air was found in his abdomen. He underwent surgery and a perforation of approximately five centimeters (two inches) was found in the duodenum, connected to a duodenal ulcer that was also discovered. The patient never really recovered from this. He subsequently had a very stormy course, with episodes of hypoperfusion, septicemia, and ultimately the family chose to withdraw life support. He did not die of liver failure, which I believe has been misunderstood by some observers here. It is highly unlikely, in our assessment, that what the patient experienced in the form of liver damage, as manifested by elevated transaminases, was attributable to the other underlying process. The death was ultimately attributed to sepsis resulting from the perforated ulcer.
- ·17 t sittenAfter yesterday's presentation, Intellia appears more robust than the share price reflects. Lonvo-z (HAE) is over-recruited in Phase III with very strong Phase I/II data, high physician and patient interest, and a realistic plan towards topline data mid-2026 and possible launch in 2027. The TTR program (nex-z) shows deep, sustained effect, and the clinical hold is due to a single patient and not a fundamental safety problem. Management is actively in dialogue with the FDA, and historically, clinical holds are typically resolved over months, not years — which could trigger a new re-rating when it happens. In the short term, many investors expect a stable consolidation around 12–14 USD. If the hold is clarified and HAELO data are strong, some analysts see an upside of +30–50 % (e.g., 15–18 USD), and in more bullish scenarios, we could see price targets above 20–30 USD, especially if commercial value starts to be priced in. It is a stock with asymmetric risk/reward: the downside is relatively subdued after bottoming out and stabilization, while the next regulatory news and data can provide clear share price movements. Overall assessment: undervalued with clear milestones to follow.·10 t sittenWith two phase-3 trials in the pipeline, it's probably a bit of a stretch to say that the downside is mitigated. There is a risk that these trials might have to be dropped entirely, the patient died after all.
- ·8.1.Intellia insider Fred E Cohen has bought 150,000 shares yesterday https://ir.intelliatx.com/node/12396/html·8.1.Exciting! Do you think there will be news soon?
- 2 päivää sitten2 päivää sittenTämä julkaisu on poistettu.
- ·12.12.2025Have positions in both Intellia, Beam and CRISPR - believe in this sector and that this is the future and play my cards broadly, most exposed to CRISPR, and smaller positions in Intellia and Beam respectively.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,35VWAP
Alin
11,34VaihtoMäärä
64,4 5 441 045
VWAP
Ylin
12,35Alin
11,34VaihtoMäärä
64,4 5 441 045
Välittäjätilasto
Dataa ei löytynyt